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Healthy lifestyles and environment produce a good state of health. A number of scientiﬁc studies support the notion that external
stimuli regulate an individual’s epigenomic proﬁle. Epigenetic changes play a key role in deﬁning gene expression patterns
under both normal and pathological conditions. As a major posttranslational modiﬁcation, lysine (K) acetylation has received
much attention, owing largely to its signiﬁcant eﬀects on chromatin dynamics and other cellular processes across species. Lysine
acetyltransferases and deacetylases, two opposing families of enzymes governing K-acetylation, have been intimately linked to
cancer and other diseases. These enzymes have been pursued by vigorous eﬀorts for therapeutic development in the past 15 years
or so. Interestingly, certain dietary components have been found to modulate acetylation levels in vivo. Here we review dietary,
metabolic, and environmental modulators of the K-acetylation machinery and discuss how they may be of potential value in the
context of disease prevention.
1.Introduction
The link of lifestyles, such as dietary patterns and physical
activity, to the risk of developing cancer and other diseases
has received support from a plethora of epidemiological
and biochemical studies. In line with this, a report from
the World Health Organization (WHO) states that cancer
causes 7.1 million deaths annually (12.5% of the global total)
and dietary factors account for about 30% of all cancers in
western countries and approximately up to 20% in develop-
ing countries (http://www.who.int/dietphysicalactivity/pub-
lications/facts/cancer/en/). The report also indicates that
diet is second only to tobacco as a preventable cause.
As developing countries become urbanized, not only does
cancer incidence increase but also the patterns tend to shift
towards those in economically developed countries. For
example, the westernized diets and lifestyles (characterized
by high calorie intake and insuﬃcient physical activity),
acquired in Japan in the past 60 years or so, are suspected
to be a signiﬁcant factor for increased incidence of breast,
liver, colon, prostate, and pancreatic cancers in the country
[1]. An important question is what are the mechanisms
underlying the epidemiological shift? There may be multiple
answers. One likely is that acquired diet and lifestyles
might have altered or reprogrammed the epigenetic makeup
of aﬀected individuals, thereby contributing to the onset
and development of cancer and other diseases. While a
person’s genetic blueprint remains relatively static, his or
her epigenetic makeup is much more dynamic and thus
susceptible to changes induced by diﬀerent diet and/or
lifestyle choices.
As a key component of the epigenetic makeup, lysine
acetylation is now recognized as one fundamental posttrans-
lationalmodiﬁcationexertingprofoundeﬀectsonchromatin
dynamics and other cellular processes in diﬀerent species [2–
4]. This modiﬁcation transfers the acetyl moiety from acetyl-
CoA to the ε-group of a lysine residue (Figure 1), which is
reversible and dynamically governed by two groups of coun-
teracting enzymes known as lysine acetyltransferases (KATs)
and deacetylases (KDACs) [5–7]. Due to historical reasons,2 International Journal of Cell Biology
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Figure 1: Cartoon illustrating acetylation and deacetylation at the
ε-amino group of a lysine residue. A KAT is responsible for transfer
of an acetyl moiety (in yellow) from acetyl-CoA to the ε-group
of a lysine residue, whereas an HDAC removes the acetyl group
fromacetyllysine,releasingacetate.Notethatsirtuinsuseacatalytic
mechanism that is completely diﬀerent from what is illustrated here
for the Rpd3/Hda1 family of deacetylases.
KDACs have almost exclusively been referred to HDACs
(histone deacetylases), so we keep the use of this acronym
hereafter.Acetylationofspeciﬁclysineresiduesonhistonesis
generally associated with transcriptional activation, whereas
histone deacetylation results in transcriptional repression
[8, 9]. However, exceptions to this general association have
been reported. For example, some HDACs are involved in or
associated with gene activation, and histone acetylation has
been linked to assembly of heterochromatin [10–13].
In addition to histones, numerous nonhistone proteins
with various functions in diﬀerent organisms and distinct
cellular compartments possess acetyl-lysine residues and
are substrates of KATs and HDACs. On the rapidly grow-
ing list of acetylated proteins are transcriptional factors,
metabolic enzymes, cytoskeleton regulators, chaperones,
signaling modulators, and even viral and bacterial pro-
teins [3, 14]. In agreement with this, the range of lysine
acetylation substrates has been recently expanded further
when proteome-wide experimentation identiﬁed thousands
of K-acetylation proteins that are important for diverse
cellular processes, which include chromatin remodeling, cell
cycle progression, RNA splicing, mitochondrial metabolism,
cytoskeleton dynamics, endocytosis, and vesicular traﬃcking
[15–19]. Thus, regulation by K-acetylation not only operates
at the level of gene expression but also acts through many
otherangles,includingenzymaticactivityorproteinstability.
Delicate control is required for maintaining an appro-
priate acetylation proﬁle for normal cellular functions. An
imbalance has been associated with various diseases. As a
result, many KAT and HDAC inhibitors, as well as activators,
have emerged as promising agents for modulating this
modiﬁcation and treating diseases whose roots originate
from altered K-acetylation. Several HDAC inhibitors have
received approval from the US Food and Drug Administra-
tion (FDA) for treating cutaneous T-cell lymphoma [20].
In addition, scientists have discovered that some dietary
components modulate KAT and HDAC activities (Figure 2),
and have analyzed lifestyles to determine factors that may
inﬂuence the functioning of these enzymes. Interestingly,
endogenous molecules have also been shown to regulate the
enzymatic activities. In what follows, we will list and review
various natural and dietary modulators of KATs and HDACs
(Figure 2), and brieﬂy discuss how cellular metabolism,
maternal diet, and environment may potentially aﬀect K-
acetylation in vivo.
2.NaturallyOccurringKATInhibitors
2.1. Diﬀerent Families of KATs. Since the very ﬁrst KATs were
identiﬁed in the mid-1990s, various mammalian proteins
have been shown to possess such enzymatic activity [5,
21–23]. The three major groups are the GNAT (Gcn5-
related N-acetyltransferases) superfamily, which includes
HAT1 (histone acetyltransferase 1), GCN5 (general control
non-derepressible 5), PCAF (p300/CBP-associated factor,
paralog of GCN5), ELP3 (elongation protein 3), ESCO1
(establishment of cohesion 1), ESCO2 (paralogous to
ESCO1), and ATAC2 (ADA2A-containing complex subunit
2); the MYST (MOZ, Ybf2/Sas3, Sas2 and Tip60) family,
which contains 5 members; and the p300/CBP family,
composed of p300 (E1A-associated protein of 300kDa) and
CBP (CREB-binding protein, paralogous to p300). A new
and more systematic nomenclature system has proposed for
these enzymes [23], but as a very recent addition to the
GNAT family, ATAC2 needs to be incorporated into the
system [24].
Both the GNAT and MYST families possess a homol-
ogous acetyl-CoA binding motif, have members in all
eukaryotes, and are evolutionarily conserved from yeast to
humans. One exception is ATAC2, which is only conserved
from ﬂy to humans although the slim mold and mushroom
appear to contain remotely related proteins. The p300/CBP
family does not display any sequence similarity to the GNAT
and MYST families, and is only conserved from the worm
to humans [25]; it is noteworthy, however, that the fungi-
speciﬁc acetyltransferase Rtt109 is a structural homolog of
p300 and CBP [26]. This pair of paralogs interacts with
numerous binding partners and is indispensable in many
critical cellular events [25]. As discussed below, they are
frequent targets of known natural KAT inhibitors (Figures 2
and 3) although some of them also act on GCN5 and PCAF
(see below) [27–29]. It is worth noting that little is known
about the impact on other KATs, so this area remains to be
developed. Moreover, only a few KAT activators have been
identiﬁed despite a logical assumption that their potential
therapeutic value can be as remarkable based on the wide use
and established value of HDAC inhibitors.
2.2. Anacardic Acid. This is the ﬁrst naturally occurring p300
inhibitor identiﬁed in 2003 (Figure 3(a))[ 30]. It can be
isolatedfromcashewnutshellextracts.Arecentreportstated
that anacardic acid also inhibits the activity of Gcn5 from
the malaria parasite Plasmodium falciparum and reduces
growth of both drug-sensitive and -resistant strains [31].International Journal of Cell Biology 3
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Figure 2:DiagramshowingeﬀectsofdietaryKATandHDACinhibition.ThecapitalletterK(inred)referstoalysineresidueandAcingreen
refers to acetylation. Diﬀerent dietary components act on distinct KATs and HDACs to produce diﬀerential cellular eﬀects depending on cell
types and conditions. On the KAT and HDAC modulators illustrated here, all are small molecules except lunasin and MCP30, which are a
43-residue polypeptide and a 30kDa protein, respectively. In addition to the inhibitors illustrated here, KAT and HDAC activators, as well
as dietary patterns (such as high fat diet, high salt ingestion, and calorie restriction) and environmental factors, may target the acetylation
machinery.
With271genesinlatetrophozoitesaﬀectedbyanacardicacid
treatment, 207 of them were down-regulated and associated
with hypoacetylation of histone H3 at lysine 9 and 14 [31].
This compound possesses antitumor properties and inhibits
p300-dependenttranscriptionfromchromatintemplatesbut
not from naked DNA templates [30].
2.3.Garcinol. Itisapolyisoprenylatedbenzophenonederiva-
tive (Figure 3(b)) from the rind of the fruit-free Garcinia
indica [32]. Garcinol has been shown to possess both antiox-
idantandanticancerchemopreventiveactivitiesinHeLacells
[32], and induces apoptosis in human leukemia cell lines
[36]. It aﬀects expression of numerous genes with oncogenic4 International Journal of Cell Biology
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Figure 3: Chemical structure of naturally occurring KAT inhibitors. (a) Anacardic acid from cashew nut shell extracts; (b) garcinol from
Garcinia indica fruit rind; (c) curcumin from Curcuma longa rhizome; (d) plumbagin from Plumbago rosea root extracts; and (e) spermidine
as an endogenous molecule [28, 32, 33].Some ofthese compounds have been modiﬁed tosynthesize more enzyme-speciﬁc inhibitors,which
a r en o td e p i c t e dh e r e[ 34, 35].
activities implicated in important cellular processes such as
apoptosis and cell cycle regulation [32], suggesting potential
value as anticancer therapeutics. As shown for anacardic
acid, garcinol inhibits p300-dependent transcription from
chromatin templates but not from naked DNA templates,
suggesting chromatin- or histone-dependent action. Com-
pared to anacardic acid, the advantage of garcinol lies in
its ability to easily permeate the cellular membrane [30,
32]. In addition, several anacardic acid- and garcinol-based
synthetic compounds have exhibited more speciﬁc eﬀects
on KATs [30, 34, 35], thereby encouraging development of
related inhibitors with higher speciﬁcity and eﬃcacy.
2.4. Curcumin. Also known as diferuloylmethane, curcumin
is a polyphenol compound (Figure 3(c)) originating from
the plant Curcuma longa. In addition to its use in traditional
Indian and Chinese medicine as a therapeutic agent, it is
often used in cuisine as a dietary spice and/or coloring agent
[37]. One advantage of curcumin over the aforementioned
two inhibitors is that it is a more speciﬁc inhibitor of p300
and CBP both in vitro and in vivo. Interestingly enough,
curcumin possesses both antioxidant and prooxidant activ-
ities, which are thought to be the cause of its anticancer
properties. At low concentrations, curcumin diminishes the
formation of reactive oxygen species (ROS), whereas the
opposite phenomenon is observed at higher concentrations
[38]. Curcumin-induced anticancer eﬀects have been by far
extensively studied and demonstrated its eﬃcacy in treat-
ment of various diseases including colon [39] and ovarian
cancers [40], metabolic diseases [41], and cardiac diseases
[42]. Curcumin was also found to induce p53 acetylation
and cause apoptosis [43]. Additionally, curcumin promotes
apoptosis in brain cancer cells in a PARP- and caspase 3-
dependent manner by inhibiting histone acetylation [37].
Moreover, both in vitro and in vivo approaches revealed a
neurogenic activity of curcumin, so one potential avenue
for the use of curcumin could be in replenishing some of
the lost neurons that patients suﬀering from cerebral trauma
experience [37]. Furthermore, HIV patients can also receive
beneﬁts from curcumin as it inhibits HIV multiplication by
inhibiting acetylation of key viral proteins such as Tat and
integrase [44]. Speaking of antiinfection, curcumin appears
to possess antiparasitic activity towards P. falciparum [45,
46].
2.5. Plumbagin. Isolated from Plumbago rosea root extracts,
plumbagin was found to potently inhibit KAT activity of
p300 in vivo [33]. Plumbagin is a hydroxynaphthoquinone
(Figure 3(d)), known in Indian ayurvedic medicine as
Chitraka [33]. Interestingly, while most KAT inhibitors have
polyhydroxyl functional groups, plumbagin has a single
hydroxyl group indispensable for the inhibitory activity on
p300. Substitution of this hydroxyl group with any other
functional groups results in complete loss of the ability to
inhibit p300 [33]. Plumbagin is highly cell-permeable and
inﬂuences crucial cellular events. For example, it potently
induces apoptosis at a high concentration partially through
the NF-κBp a t h w a y[ 47]. Since p300-mediated acetylation
is required for NF-κB activation, speciﬁc inhibition of p300
prevents the activation [33, 47]. In addition to histones,
inhibition of p300 aﬀects other nonhistone protein acetyla-
tion [33]. Emerging data also support biological relevance
of this compound in neuroprotective, antibacterial, and
anticarcinogenic activities [48–50], although inhibitory roles
of plumbagin towards KATs in these cases remain to be
investigated. In this way, plumbagin appears to be a potential
useful agent for the prevention and treatment of various
diseases, although plumbagin’s high cellular toxicity limitsInternational Journal of Cell Biology 5
its therapeutic applications [33]. Future development of
synthetic analogues with lower toxicity shall circumvent this
problem.
2.6. Lunasin. While the aforementioned 4 inhibitors are
small molecules (Figures 3(a)–3(d)), lunasin is a 43-residue
polypeptide. Derived from soy, barley, and wheat, luasin
has cancer-chemopreventive value [51]. It has also been
isolated from Solanum nigrum L., a plant that is indigenous
to northeast Asia and has been traditionally used in oriental
medicine [52, 53]. It was found that lunasin substantially
inhibits activities of yeast Gcn5 and mammalian PCAF,
resulting in decreased histone H3 and H4 acetylation [51–
53]. Decrease in histone acetylation was perceived to occur
simultaneously with inhibition of RB phosphorylation [51].
The binary eﬀects on inhibition of histone acetylation
and Rb phosphorylation by lunasin result in core histone
hypoacetylationandcellcyclearrest,whichwillconsequently
render the cells abnormal, inhibit cell growth, and/or induce
cell death. Oral administration is the main route for its
cancer-preventive eﬀects, so it is important to ensure that
lunasinisabsorbedandremainsintactwhenreachingthesite
of action [51].
2.7. Spermidine. The intracellular concentration of spermi-
dine, a natural polyamine (Figure 3(e)), decreases with aging
[54]. Interestingly, a recent study found that spermidine pro-
moteslongevity[55].Severalorganismsincludingyeast,ﬂies,
worms, mice, and human cells exhibit antiaging eﬀects upon
treatment with spermidine. Furthermore, an autophage-
dependent mechanism seems to be at the origin for
the prolonged life span. In addition, spermidine-mediated
induction of longevity was associated with hypoacetylation
at several lysine residues located at the N-terminal part of
histone H3 and the spermidine-mediated anti-ageing eﬀect
phenocopied the knockout of KATs [55]. Although these
results were produced by exogenous treatment of spermi-
dine,consideringthatitsconcentrationdecreaseswithageing
and the KAT knockout phenocopies the stimulatory eﬀects
of spermidine in lifespan, it may function as an endogenous
KATinhibitortoregulategeneexpressionprograminageing.
3.DietaryandEndogenous HDACInhibitors
3.1. Two Diﬀerent Families of HDACs. Compared to KATs,
HDACs have been much more vigorously pursued as drug
targets for cancer and other diseases. This is at least in part
due to the fact that the ﬁrst speciﬁc inhibitor trichostatin
A was found to inhibit both cell proliferation and HDAC
activity [56]. In humans, there are 18 known HDACs,
which are divided into two families, based on sequence
similarity to yeast orthologs, and catalytic mechanisms
[57, 58]. The ﬁrst 11 members, HDAC1–11, belong to
the Rpd3 (reduced potassium dependency 3)/Hda1 (histone
deacetylase 1) family and are further grouped into three
classes: I (HDAC1, 2, 3 and 8), II (HDAC4, 5, 6, 7, 9 and 10),
a n dI V( H D A C 1 1 )[ 59]. The remaining seven are members
of the Sir2 (silent information regulator 2) or sirtuin (Sir2-
related protein) family and thus known as sirtuins 1–7 (or
SIRT1–7) [60, 61]. They have also been referred to class III.
While the Rpd3/Hda1 family members are Zn
2+-dependent
enzymes, sirtuins require NAD+ as a cofactor. Because of
this, the modulators can be divided into two diﬀerent groups
according to which family of HDACs is the target. Most
known inhibitors, including those listed in Figure 4 and
discussed below, act on the Rpd3/Hda1 family.
3.2. Butyrate. Fermentation of dietary ﬁbers by colonic bac-
teria produces severalshort chainfattyacids as endproducts,
oneofwhichisbutyrate(Figure4(a))[65].Thisisonereason
for beneﬁcial eﬀects of dietary ﬁbers. Butyrate was the ﬁrst
HDAC inhibitor identiﬁed in the late 1970s [66–68], and it
might also be the smallest HDAC inhibitor known [62]. It
aﬀects diverse cellular processes, including gene expression,
DNA synthesis, cell proliferation, and morphology [69].
Butyrate has a simple structure containing three carbons
attached to a carboxylic acid group (Figure 4(a)), which is
presumed to ﬁt into the active site of HDACs and forms a
bidentate ligand with zinc
2+ buried there [70, 71]. Butyrate
inhibitsactivitiesofmostmembersoftheRpd3/Hda1family,
but not HDAC6 and HDAC10 [72].
In the context of cancer, it was observed that butyrate
induces apoptosis through the action of PKC-δ and caspase
3, as well as suppresses survival eﬀects of secondary bile
acids in colon adenoma and cancer cell lines [65]. In another
study, butyrate was shown to inhibit the recruitment of
HDAC to the p21 promoter, thereby inducing the expression
of p21 and concomitantly retarding cell proliferation [72].
Inhibition of HDAC activity by butyrate increases histone
acetylation levels mediated by p300 at the promoter regions,
leading to chromatin opening, p21 gene expression, and
inhibition of E-Cdk2, which causes cell cycle arrest [72].
Apart from butyrate’s anticancer capabilities, a mounting
body of evidence points to multiple anti-inﬂammation
roles: it can induce neutrophil apoptosis during systemic
inﬂammation by activating the caspase cascade [73]; in
neurodegenerative diseases such as spinal and bulbar mus-
cular atrophy (SBMA), amelioration was seen after the oral
administration of butyrate [74]; in the immune response
butyrate inhibits IL-12 and TNF-α expression in monocytes
[75], and in enteric neuroplasticity which is associated with
increased histone H3 acetylation at lysine 9 [76].
Interestingly, a recent report showed that tributyrin, a
prodrug of butyrate present in milk fat and honey, possesses
more potential pharmacokinetic properties and is better
tolerated orally than butyrate itself [77].
3.3. Sulforaphane (SFN). An isothiocyanate (Figures 4(b)
and 4(c)), SFN is derived from glucoraphanin and rich
in cruciferous vegetables such as broccoli and broccoli
sprouts. It was initially found as a potent inducer of
phase 2 detoxiﬁcation enzymes. However, the implication of
SFN in inhibition of HDAC activity has gained particular
attention [78]. Like other isothiocyanates, SFN is generated
via the mercapturic acid pathway [79]. As the metabolized6 International Journal of Cell Biology
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Figure 4: Chemical structure of dietary and endogenous inhibitors of HDACs. (a) butyric acid, acid form of butyrate, a product from
dietary ﬁber fermentation by gut bacteria; (b, c) sulforaphane cysteine and sulforaphane N-acetyl-cysteine from cruciferous vegetables; (d,
e) allyl mercaptan and diallyl disulﬁde from garlic; and (f) sphingosine-1-phosphate [62–64]. These compounds are either naturally or
endogenously occurring, and they act on diﬀerent members of the Rpd3/Hda1 family. The structures may be used as templates to generate
more speciﬁc compounds with higher speciﬁcity and eﬃcacy.
products of this pathway, both SFN-cysteine (SFN-Cys) and
SFN-N-acetylcysteine (SFN-NAC) function as active HDAC
inhibitors [80]. Compared to other HDAC inhibitors such as
trichostatin A and SAHA (which act eﬃciently at nanomolar
to low micromolar concentrations), SFN is a weak dietary
inhibitor that requires a higher concentration to function
[62, 71]. A pilot study has been performed to document
the inhibitory eﬀects of SFN on HDACs in vivo. In healthy
volunteers ranging from 16–55 years of age without any
history of nonnutritional supplement use, an intake of 68g
of broccoli sprouts with a bagel and cream cheese after 48
hours refraining from cruciferous vegetable consumption
inhibited HDAC activity in peripheral blood mononuclear
cells as early as 3 hours after consumption of the broccoli
sprout [63]. The inhibitory eﬀect of SFN on HDACs was
also detected in human breast cancer cells [79, 81]. SFN
showed anti-cancer properties by inhibiting HDAC activity,
stimulating expression of proteins responsible for breast
cancer cell proliferation and cell growth, and activating
cell cycle arrest and apoptosis [81]. Furthermore, the study
showed a signiﬁcant reduction in expression of GFR, HER-
2 and ER, the markers for breast cancer proliferation and
clinical diagnosis. The induction of apoptosis in human
breast cancer cell lines by SFN suggests that the caspase
pathway might be involved. Future elucidation is required
to examine the ability of SFN to inhibit HDAC activity
on speciﬁc promoters since signiﬁcant changes in global
acetylation were not detected [81].
In prostate cancer, SFN treatment inhibited HDAC6,
resulting in hyperacetylation of HSP90, disruption of the
HSP90-androgen receptor (AR) interaction, and conse-
quently, proteolytic degradation of AR [82]. Targeting AR by
SFN is a therapeutically viable strategy for the treatment of
prostate cancer since AR is the central protein in prostate
cancer signaling. In line with this, AR’s inactivation has
been demonstrated as a promising strategy in preclinical
studies and clinical trials [82]. Synergistic eﬀects of SFN
with polyphenol [-] epigallocatechin-3-gallate (EGCG), a
compound found in green tea, have also been observed
in human colon carcinoma cells [83]. EGCG is known to
suppress colonic tumorigenesis in animal models and in
epidemiological studies as well as to induce senescence in
leukemic cells [83] .W h e nt a k e ni nc o m b i n a t i o n ,S F Na n d
EGCG attenuated the cellular senescence induced by EGCG
and synergistically activated AP-1, a redox-sensitive tran-
scription factor that regulates gene expression in response
to oxidative and electrophilic stresses [83]. This approach
may open new therapeutic methodology that diﬀerent
dietary agents function cooperatively to ﬁght oﬀ cancer
cells. Another study has demonstrated that SFN induces
expression of an antimicrobial peptide called human β-
defensin-2 in intestinal epithelial cells, implying the use of
SFN not only in cancer but also in prevention and combat of
bowel disorders such as Crohn’s disease [84].
3.4. Allyl Mercaptan. Among organosulfur compounds
derived from garlic, allyl mercaptan (AM, Figure 4(d))
achieves the greatest HDAC inhibition in vitro [64]. The
inhibitory eﬀect of AM on HDACs was detected in a dose-
dependent manner within 10min of exposure. In HT29
human colon cancer cells, AM treatment induced p21
expression and recruitment of Sp3 and p53 to the promoter.
This coincided with growth inhibition and cell cycle arrest
in G1. Structural analysis of AM binding to HDAC8 revealed
thatAMﬁtsintothecatalyticcenterwithoutsterichindrance
and is predicted to make hydrophobic interactions with
residues in the cleft of HDAC8. Moreover, the predicted
driving force of AM binding to the HDAC8 active siteInternational Journal of Cell Biology 7
was suggested to be strong by the remarkably low free
energy (−120kcal/mol) in the interaction between zinc from
HDAC8 and sulfur from AM [64].
Another organosulfur compound, diallyl disulﬁde
(DADS, Figure 4(e)) has pleiotropic eﬀects on various
cellular events by modulating HDAC inhibition. DADS
is a natural organosulfur compound found in garlic and
accounts for 40%–60% of the total lipid-soluble sulﬁde
in garlic oil [85]. In human colon adenocarcinoma cell
lines, DADS treatment showed induction of G2 cell cycle
arrest and inhibition of cell proliferation [86]. In rodent
models, DADS inhibits the initiation and promotion phases
of chemically induced carcinogenesis in digestive tracts such
as colon, kidney, and stomach. The anticarcinogenic eﬀect
of DADS was due to its ability in inhibiting HDACs and
causing hyperacetylation and induction of p21Waf1 gene
expression, concomitant with increase in acetylation levels
of histone H4 and H3 [86].
3.5. MCP30. A 30kDa protein extracted from seeds of the
bitter melon Momordica charantia, designated as MCP30
(Momordica charantia protein of 30kDa), was recently
found to inhibit HDAC1 activity and promote H3 and
H4 acetylation in several neoplastic prostate cell lines [87].
MCP30 induces apoptosis in premalignant and malignant
prostate cells. Furthermore, these cells are marked by activity
upregulation of HDAC1, whose expression and activity is
selectivelyinhibitedupontreatmentwithMCP30[87].These
eﬀects of MCP30 are associated with derepressed expres-
sion of PTEN, whose inactivation is highly signiﬁcant in
development of prostate cancer, inhibition of Wnt signaling,
and decreased expression proﬁles of proteins, such as c-Myc
and cyclin D1, known to control cell-cycle progression and
apoptosis [87].
3.6. Nitric Oxide (NO). The ﬁrst endogenous HDAC
inhibitor to be identiﬁed is nitric oxide, which selec-
tively inhibits the activity of HDAC2. NO is generated by
stimulation of brain-derived neurotrophic factor (BDNF)
signaling and it nitrosylates cysteine 262 and 274 [88].
Interestingly, it was found that S-nitrosylation of HDAC2
does not inhibit the enzymatic activity, but rather facil-
itates removal of HDAC2 from chromatin and results in
hyperacetylation of histones at the promoters of genes
involved in neuronal development, which in turn causes
activation of gene expression [88]. In another study, S-
nitrosylation of HDAC2 by NO donors was observed to
impair the enzymatic function of HDAC2 in dystrophin-
deﬁcient MDX mice, suggesting a diﬀerent mechanism by
whichNOmediatesS-nitrosylationofHDAC2[89].NOmay
also interfere with the binding of HDAC to gene promoter
regions in the nucleus and inhibit the HDAC enzymatic
activity in cytoplasm [90]. Taken together, these studies
demonstrate that when an altered HDAC activity or expres-
sionisobserved,suchasDuchennemusculardystrophy[89],
inhibition of HDAC2 in an NO-dependent manner could be
an interesting avenue to explore for the treatment of related
diseases.
3.7.Sphingosine-1-Phosphate(S1P). Recentdatashowedthat
sphingosine-1-phosphate (Figure 4(f))a c t sa sa ne n d o g e -
nous inhibitor of HDAC1 and 2 [91]. Inhibition of the
enzymatic activity by S1P was comparable to that of a well-
known HDAC inhibitor, trichostatin A [91]. Subsequent
mass spectrometry analysis revealed that S1P sits in the
active site of HDAC1 or 2 for inhibiting the catalytic activity.
S1P and SphK2, one isoenzyme responsible for synthesis of
S1P, are present in a transcriptional corepressor complex
containing HDAC1 and 2 [91]. In addition, interaction
between SphK2 and puriﬁed core histones was observed
and correlated with acetylation of speciﬁc lysine residues
on core histones [91]. As witnessed in the case of butyrate,
many HDAC inhibitors induce expression of p21; similarly,
overexpression of SphK2 results in lysine 9 hyperacetylation
of histone H3 at the p21 promoter [91], suggesting that
SphK2 suppresses HDAC activity and promotes histone
acetylation and p21 expression. Importantly, the discovery of
endogenousHDACinhibitorssuchasNOandS1Ppointsout
a novel approach in targeting HDACs.
4.DietarySirtuinActivationandMetabolic
Impact on K-Acetylation
4.1. Dietary Sirtuin Activation. A natural and polyphenolic
phytoalexin, resveratrol is present in grape skins and red
wines, and is known to possess phytoestrogenic and antiox-
idant properties [92]. In addition, resveratrol also exists in
a number of fruits, including mulberry, bilberry, cranberry
and blueberry, as well as in peanuts [93]. A previous study
has shown that resveratrol possesses diverse biochemical
and physiological properties with health beneﬁts, such as
longevity enhancement, cardioprotection, anti-aging, anti-
cancer activity, anti-inﬂammation, and neuroprotection [92,
93]. Intake of resveratrol alone and in combination with
genistein, a major isoﬂavone found in soy, suppressed
prostate cancer development in the SV-40 Tag rat model
[94]. Also, beneﬁcial metabolic eﬀects induced by resveratrol
have been observed in mice, for example, increase in aerobic
capacity (increased running time and oxygen consumption
in muscle ﬁbers) [95]. The increase was attributed to
induction of gene involved in oxidative phosphorylation
and mitochondrial biogenesis. PGC-1α, a gene involved
in mitochondrial biogenesis and function [95], is partly
responsible for the observed changes. It seems that decreased
PGC-1α acetylation is the cause for an increase in its
activity. Reduced acetylation in PGC-1α and its subsequent
elevation in functional capability were attributed to SIRT1,
which interacts with and deacetylates PGC-1α at multiple
lysine sites [95]. SIRT1, a member of the class III sirtuin
family, senses the cellular energy by rise in the NAD+/NADH
ratio and stimulates fat utilization to prevent diet-induced
metabolicdiseases[96].Ithasbeensuggestedthatresveratrol
activates SIRT1 in part by mimicking physiological pathways
that activates SIRT1 such as caloric restriction (CR) [96]. A
number of reports proposed that resveratrol also increases
longevity. In fact, resveratrol treatment increased longevity
of several model organisms including yeast, worm, and ﬂy8 International Journal of Cell Biology
via sirtuin-dependant mechanisms [97, 98]. Resveratrol was
also shown to extend lifespan of a short-lived species of ﬁsh,
N. furzeri, by nearly 60% although the action of sirtuins
involved in this eﬀect has not been assessed [99]. The roles
of the sirtuin family have been implicated in CR-mediated
life span extension as well. One of the factors responsible
for ageing in yeast is accumulation of extrachromosomal
rDNA circles [100]. A higher ratio of NAD+/NADH caused
by CR triggers Sir2 activation [101] and activated Sir2 then
proceeds to induce chromatin silencing at the rDNA loci,
thereby repressing the production of toxic rDNA circles
[102].
However, there seems to have arisen a schism in the role
of resveratrol or sirtuin activators in extension of lifespan
in mammals. Two groups reported that resveratrol activates
SIRT1 in vitro in a ﬂuorescent-labeling-dependent manner,
raising a debate if resveratrol even activates the sirtuins and
if resveratrol does so in indirect mechanisms [103, 104].
In addition, the ability of resveratrol to extend lifespan has
been questioned: only slight extension of lifespan had been
observed in worms treated with resveratrol independently of
Sir2 and no lifespan extension had been seen in ﬂies, thereby
contradicting some early studies [105]. Also, CR and resver-
atrol may induce longevity through sirtuin-independent
pathways in mammals [106]. It was reported that CR and
Sir2 overexpression in a yeast strain did not often extend
lifespanandexhibitedanadditiveeﬀectonlifespanextension
of yeast, suggesting they work through diﬀerent mechanisms
[107]. Consistently, resveratrol treatment exhibited a similar
increase in neuronal survival of both Sir2 homozygous null
ﬂies and ﬂies with normal Sir2 levels, likely operating in a
Sir2-independent mechanism [108]. It was also found that
CR showed more extended lifespan in a Sir2 knockout yeast
strain than in the wild-type strain [107]. Furthermore, the
sirtuins sometimes may limit lifespan rather than extend it
[106]. This was shown by experimental results where Sir2
reduced chronological lifespan in yeast during the period of
CR [109], suggesting that Sir2, instead of anti-aging activity,
might induce aging in at least some types of mammalian
cells and tissues. Overall, this is an actively debated research
area [110, 111], so additional studies will be needed to
fully elucidate the underlying molecular mechanisms of
action.
4.2. Metabolic Impact on K-Acetylation. Metabolic states are
tightly linked to regulation of the K-acetylation machinery.
During fasting and feeding, cellular energy and metabolic
s t a t e sa r er e ﬂ e c t e di nﬂ u c t u a t i o n si nl e v e l so fN A D + and
acetyl-CoA [112]. Upon feeding, the levels of acetyl-CoA,
coenzyme of KATs, increase (Figure 1). Increased KAT
activity then causes changes in chromatin dynamics and
leadstothedevelopmentofacertainepigeneticproﬁle[112].
On the other hand, fasting elevates cellular NAD+ levels and
leads to activation of sirtuins. Activated sirtuins then target
chromatin and induce histone hypoacetylation to regulate
gene expression according to the fasting state.
Some of these principles have been evaluated in animal
models. Two years ago, a group generated transgenic mice
overexpressingSIRT1(SirBACOmice)inthepursuitofiden-
tifying metabolic beneﬁts that stem from the modulation
of sirtuins [113]. SirBACO mice demonstrated a decrease
in food intake and locomotor activity on a standard diet.
Furthermore, SirBACO mice displayed diabetes-preventive
eﬀects, such as increased energy eﬃciency, which protects
them from insulin resistance and hyperglycemia when they
were put on a high-fat diet [113]. The study reveals an
underappreciated role of sirtuins as cellular metabolism
regulators. By analogy, activation of SIRT1 by a speciﬁc
SIRT1 activator called SRT1720 shows preventive eﬀects in
metabolic disorders induced by a high calorie intake such
as increased insulin sensitivity, increased fat oxidation, and
suppressed obesity [96].
It has been known for decades that a reduction of
calorie intake signiﬁcantly lowers the rate of aging in
mammals and decreases the risk of many age-related dis-
eases, such as cancer and neurodegeneration [114]. For
example, CR induced attenuation of Aβ peptides in brain
tissues from mice by activating SIRT1, thus preventing
Alzheimer disease-type amyloid neuropathology [115]. CR
also induces SIRT3 expression, which plays an important
role in fatty-acid oxidation; mouse expressing no SIRT3
exhibited impaired fatty-acid oxidation as well as elevated
accumulation of fatty-acid oxidation intermediates and
triglycerides in liver during fasting [116]. This increase in
SIRT3 expression led to deacetylation and activation of the
fatty-acid oxidation enzyme named LCAD (long-chain acyl
coenzyme A dehydrogenase), potentiating a link between
CR-induced SIRT3 activation and fatty-acid oxidation. In
line with this, SIRT3 is an important sirtuin responsible
for change of acetylation during CR [117]. A proteomic-
wide survey revealed that among 287 unique acetylated
proteins from mouse liver, 165 of them (about 57%) are
mitochondrial proteins [117]. Among 165 mitochondrial
proteins, 72 proteins were identiﬁed as candidates changing
in acetylation upon CR. In addition, numerous Salmonella
enterica proteins in central metabolism are acetylated, and
acetyl-lysine residues are present in many mitochondrial
proteins of mammalian cells and liver [15, 17, 18], further
suggesting an intimate link between lysine acetylation and
metabolism. Thus, it is reasonable to speculate that feeding
behaviors and many metabolites will be found to target and
modulate the acetylation machinery.
5. Impact of lifestyles and Environmenton
the K-Acetylation Machinery
5.1. Eﬀect of Lifestyle Choices on Acetylation. As important
as what kind of food a person has, how much he/she
takes also aﬀects the person’s epigenetic state. Changes in
carbohydrate/fat ratio in diet were found to alter acetylation
of histone H3 and H4 on the sucrose-isomaltase gene [118].
A high carbohydrate diet intake enhances SI gene expression
withincreasedacetylationlevelsofhistoneH3andH4onthe
enhancer/promoter and transcription regions of the sucrose-
isomaltase gene [118]. Similarly, high-salt diet was found
to induce the expression of salt-inducible kinases, whichInternational Journal of Cell Biology 9
inhibit the action of HDAC5 [119]. Other lifestyle choices
are also important factors contributing to disease devel-
opment through altered acetylation. For example, smoking
was reported to alter expression of class I/II HDACs in
heavy smokers [120]. It was also reported that decreased
HDAC activity by cigarette smoking was associated with
induction of authophagy in chronic obstructive pulmonary
disease (COPD) [121]. Moreover, substance abuse has been
linked to altered histone acetylation. Chronic consumption
of alcohol increases global acetylation of hepatic proteins
and may induce liver injury [122]. Cocaine-induced neural
and behavioral plasticity has been linked to altered histone
acetylation [123].
5.2. Impact of Emotional Well-Being on Acetylation. Inter-
estingly, emotional and psychological conditions have been
implicated with HDACs and thus HDAC inhibitors. Tran-
sient decrease with a subsequent increase in acetylation
of histone H3 was observed in the nucleus accumbens of
mice that have undergone chronic social defeat stress [124].
Persistent increase in H3 acetylation was associated with
a decreased level of HDAC2 in the nucleus accumbens.
Chronic stress followed by delivery of butyrate into the
nucleus accumbens generated robust antidepressant-like
eﬀects validated in several behavioral assays. Supportively,
investigation in pursuit of beneﬁcial value of butyrate in
treating traumatic brain injury (TBI) found that concurrent
butyrate treatment with behavioral training such as the
Morris water maze task improved learning and memory in
brain-injured mice [125], suggesting a role of HDACs in
brain function. Related to this, HDAC5 mediates behavioral
adaptation to emotional stimuli [126].
5.3. Link to Maternal Diet and Care to Oﬀsprings’ Acetylation.
There is evidence suggesting that the maternal diet regulates
gene expression and contributes to disease development in
oﬀsprings. Prenatalmaternaldiet withsupplementofmethyl
donors has been shown to be associated with a higher risk
of asthma characterized by a greater airway allergic inﬂam-
mation and IgE production in F1 and F2 progenies [127].
It is likely that these eﬀects involve diﬀerential epigenetic
regulations caused by the maternal diet, behavior, and other
factors. Supporting this notion, it was demonstrated that
chronic consumption of maternal high-fat diet results in
increased triglycerides and nonalcoholic fatty liver diseases,
which are accompanied by signiﬁcant hyperacetylation of
histone H3 in fetal hepatic tissue at lysine 14, 9, and 18 [128].
Interestingly, maternal care exerts profound impact on
oﬀsprings’ gene expression and epigenetic states [129, 130].
It was recently found that the hippocampus of oﬀsprings of
the high and low pup licking/grooming (LG) and arched-
back nursing (ABN) mothers exhibits diﬀerent program-
ming of the glucocorticoid receptor (GR) gene promoter.
Diﬀerent maternal behaviors produced diﬀerence in histone
acetylation,DNAmethylationandinteractionoftheGRpro-
moter with the transcription factor NGFI-A (nerve growth
factor-inducible protein A) [131]. In addition, childhood
abuse was found to aﬀect methylation of the GR promoter in
the brains of analyzed human subjects [132]. As functional
impact of DNA methylation is often linked to histone
deacetylation, maternal care might also regulate acetylation
proﬁles in the oﬀsprings. Furthermore, maternal aging was
positively correlated with acetylation of histone H4 at lysine
12 in murine oocytes, which may further exert impact on
fertilization and embryo development [133]. Taken together,
external factors such as maternal diet and care could change
the epigenetic program during development in utero as
well as postnatally, thereby linking maternal factors to the
epigenomic proﬁle of an oﬀspring.
5.4. Impact of Environmental Toxins on Acetylation. In
addition to social and maternal environment, physical envi-
ronment may aﬀect acetylation of an individual. Exposure
to an organochlorine pesticide called dieldrin was recently
reported to play a role in apoptotic cells death in dopamin-
ergic neuronal cells [134]. Dieldrin treatment induced
acetylation of histone H3 and H4, which was associated with
altered proteasomal activity and accumulation of CBP [134].
Further studies are needed to extrapolate cell-based ﬁndings
to humans, but one immediate implication is that exposure
to environmental toxins like dieldrin may directly impact the
acetylation machinery.
6. ConcludingRemarksandFuturePerspectives
Since it was initially discovered and chemically deﬁned
in the 1960s [135, 136], acetylation of lysine residues on
histones has gained much attention due to its important
role in regulating gene expression and other chromatin-
templated nuclear processes. As discussed above, potential
nutritional or dietary components act through the K-
acetylation machinery. Various studies suggest that this is an
emerging and promising area of translational research, but
vigorous criteria and eﬀorts are needed to ﬁrmly establish
a potential link, for example, how speciﬁc the link might
be, and how it might ﬁt in the existing literature about the
biochemistry and biology of related KATs and HDACs. For
example, biochemical studies have ﬁrmly established that
GCN5 could be part of diﬀerent multiple protein complexes
[5, 137], so an interesting question is which complex should
be the target of a potential modulator. A similar question can
be raised for modulators of HDAC1 and HDAC2, both of
which are part of multiple protein complexes [58, 59]. This
way, related studies from diﬀerent angles will synergize to
facilitate the learning process about these enzymes and their
regulators.
Inadditiontohistones,thousandsofnonhistoneproteins
are also subject to K-acetylation [15–19], so an interest-
ing research direction would be how the inhibitors and
activators (Figure 2) may regulate acetylation of these
nonhistone proteins. This modiﬁcation crosstalks with other
phosphorylation, methylation, ubiquitination, and other
posttranslational modiﬁcations to regulate protein functions
in a coordinated fashion [3] .T h u s ,i ti sf a i rt oc o n c l u d et h a t
K-acetylation(Figure1)hasemergedasonemajorregulatory
mechanism in diverse biological systems from bacteria to10 International Journal of Cell Biology
humans. This has naturally led to rapid expansion of the
research ﬁeld about the responsible enzymatic machinery
composed of KATs and HDACs (Figure 1), and has also
resultedinthedevelopmentanddiscoveryofmanyinhibitors
and activators of these enzymes, including those discussed
above (Figures 3 and 4). Owing to their diverse roles in
diﬀerent cellular process, modulation of KATs and HDACs
by inhibitors or activators has shed novel light on drug
development and will likely become an important way for
treating a variety of diseases.
Just like environmental factors, dietary KAT and HDAC
modulators are examples of dynamic regulators, which upon
chronic exposure can modulate the cellular K-acetylation
proﬁle and imprint an individual’s epigenetic makeup that
may be static enough to last throughout his/her lifetime.
One important question is what quantity of food needs
to be ingested for these KAT and HDAC modulators to
reach a physiologically relevant concentration at which they
can either activate or inhibit KATs and HDACs to elicit
disease-preventive eﬀects. In this respect, sodium butyrate
has been shown to cause cell cycle arrest and apoptosis at a
concentration achievable in the colon by ﬁber consumption
[138]. A similar conclusion has been reached in a pilot study
involving the use of SFN in healthy volunteers [63]. Foods
in diﬀerent combinations could also represent how dietary
modulators of KATs and HDACs confront human diseases.
In addition, a better understanding of the pharmacokinetic
makeup will help quantify the amount of food required
for one to ingest and reach a therapeutic concentration.
Another interesting question is whether more natural KAT
and HDAC inhibitors or activators present in food or dietary
agents remain to be identiﬁed (Figure 2). If so, the yet-to-
b e - d i s c o v e r e dK A Ta n dH D A Cm o d u l a t o r sc o u l db ev e r y
interesting research subjects, as they will open new avenues
for drug development.
Besides synthetic and naturally occurring compounds,
emerging evidence supports the existence of endogenous
KAT and HDAC regulators (Figures 3 and 4) and yields new
insights into the development of novel therapeutic strategies
that can target KATs and HDACs more speciﬁcally. Whether
more endogenous KAT and HDAC modulators remain to
be identiﬁed is an important question awaiting further
investigation.
Major diseases such as cancer, diabetes, and heart
disorders are often chronic, so in addition to therapeutic
approaches, prevention is an important strategy for com-
bating and managing these diseases. One relevant question
is how to develop eﬀective plans. As discussed above,
daily activities of an individual, including food intake,
physical activity, emotional well-being, physical and social
environment, and other factors all seem to impact the K-
acetylationmachinery.Sincethemodiﬁcationcrosstalkswith
various regulatory mechanisms, daily activities may in turn
aﬀect epigenetic and other biological regulations. As we
have witnessed in the past two decades the explosive studies
of KATs, HDACs and their potential therapeutic value in
treating and preventing cancer and other diseases, future
investment and discoveries in this and related research areas
will continue to generate not only novel and rich scientiﬁc
knowledge but also practical information on how we can
carefully manage daily activities as a life-long project for
preventing diseases and improving the quality of life in the
long run.
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